These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 28369700)

  • 41. [Mastocytosis, classification, biological diagnosis and therapy].
    Arock M
    Ann Biol Clin (Paris); 2004; 62(6):657-69. PubMed ID: 15563424
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Routine abdominal ultrasonography has limited value in the care for patients with indolent systemic mastocytosis.
    de Mol CL; Hermans MAW; Gerth van Wijk R; van Hagen PM; van Daele PLA
    Hematology; 2017 Oct; 22(9):544-547. PubMed ID: 28486845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mastocytosis among elderly patients: A multicenter retrospective French study on 53 patients.
    Rouet A; Aouba A; Damaj G; Soucié E; Hanssens K; Chandesris MO; Livideanu CB; Dutertre M; Durieu I; Grandpeix-Guyodo C; Barète S; Bachmeyer C; Soria A; Frenzel L; Fain O; Grosbois B; de Gennes C; Hamidou M; Arlet JB; Launay D; Lavigne C; Arock M; Lortholary O; Dubreuil P; Hermine O; Georgin-Lavialle S
    Medicine (Baltimore); 2016 Jun; 95(24):e3901. PubMed ID: 27310990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
    Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
    Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
    De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
    Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mastocytosis: a comprehensive insight.
    VAN Gysel D; DE Maeseneer H; Oranje AP
    G Ital Dermatol Venereol; 2016 Aug; 151(4):385-96. PubMed ID: 27070304
    [TBL] [Abstract][Full Text] [Related]  

  • 47. KIT(D816V+) systemic mastocytosis associated with KIT(D816V+) acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation.
    McClintock-Treep SA; Horny HP; Sotlar K; Foucar MK; Reichard KK
    J Clin Pathol; 2009 Dec; 62(12):1147-9. PubMed ID: 19729359
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Systemic mastocytosis: bone impact].
    Spivacow FR; Sarli M; Nakutny R
    Medicina (B Aires); 2012; 72(3):201-6. PubMed ID: 22763156
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A transgenic zebrafish model expressing KIT-D816V recapitulates features of aggressive systemic mastocytosis.
    Balci TB; Prykhozhij SV; Teh EM; Da'as SI; McBride E; Liwski R; Chute IC; Leger D; Lewis SM; Berman JN
    Br J Haematol; 2014 Oct; 167(1):48-61. PubMed ID: 24989799
    [TBL] [Abstract][Full Text] [Related]  

  • 50. KIT D816V mutation-positive cell fractions in lesional skin biopsies from adults with systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB
    Dermatology; 2013; 226(3):233-7. PubMed ID: 23774045
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FDG-PET/CT findings in systemic mastocytosis: a French multicentre study.
    Djelbani-Ahmed S; Chandesris MO; Mekinian A; Canioni D; Brouzes C; Hanssens K; Pop G; Durieu I; Durupt S; Grosbois B; Besnard S; Tournilhac O; Beyne-Rauzy O; Agapé P; Delmer A; Ranta D; Jeandel PY; Georgin-Lavialle S; Frenzel L; Damaj G; Eder V; Lortholary O; Hermine O; Fain O; Soussan M
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2013-20. PubMed ID: 26140850
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Abnormal bone marrow histopathology in paediatric mastocytosis.
    Carter MC; Metcalfe DD; Clark AS; Wayne AS; Maric I
    Br J Haematol; 2015 Mar; 168(6):865-73. PubMed ID: 25429914
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.
    Paul C; Sans B; Suarez F; Casassus P; Barete S; Lanternier F; Grandpeix-Guyodo C; Dubreuil P; Palmérini F; Mansfield CD; Gineste P; Moussy A; Hermine O; Lortholary O
    Am J Hematol; 2010 Dec; 85(12):921-5. PubMed ID: 21108325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cutaneous mastocytosis in adults. evaluation of 14 patients with respect to systemic disease manifestations.
    Tebbe B; Stavropoulos PG; Krasagakis K; Orfanos CE
    Dermatology; 1998; 197(2):101-8. PubMed ID: 9732155
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of the basophil-specific antibodies 2D7 and BB1 in patients with cutaneous Mastocytosis.
    Idoate MA; Echeveste J; Gil P; Sanz ML; Ferrer M
    J Investig Allergol Clin Immunol; 2013; 23(6):392-7. PubMed ID: 24459815
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease.
    Gülen T; Hägglund H; Dahlén B; Nilsson G
    J Intern Med; 2016 Mar; 279(3):211-28. PubMed ID: 26347286
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diffuse cutaneous mastocytosis: report of a severe case with fatal outcome.
    Ghiasi M; Ghanadan A; Jesri SB; Sotudeh S; Ramyar A
    Dermatol Online J; 2011 Mar; 17(3):7. PubMed ID: 21426873
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ["Smoldering systemic mastocytosis. "Successful therapy with cladribine].
    Schleyer V; Meyer S; Landthaler M; Szeimies RM
    Hautarzt; 2004 Jul; 55(7):658-62. PubMed ID: 15241520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Systemic mastocytosis with progressive disease course].
    Várkonyi J; Szombath G; Vályi-Nagy A; Csomor J; Egedi K; Kovalszky I; Tölgyesi K; Szerafin L; Tóth L; Soós G; Masszi T
    Orv Hetil; 2018 Feb; 159(5):192-196. PubMed ID: 29376426
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.
    Teodosio C; García-Montero AC; Jara-Acevedo M; Alvarez-Twose I; Sánchez-Muñoz L; Almeida J; Morgado JM; Matito A; Escribano L; Orfao A
    Leukemia; 2012 May; 26(5):951-8. PubMed ID: 22051531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.